Pipeline

August 24, 2020
Company Drug/Device Medical Condition Status
COVID-19 Trials and Actions
Algernon Pharmaceuticals NP-120 (Ifenprodil) hospitalized patients with confirmed COVID-19 first patient enrolled in the U.S. in phase 2b/3 trial
Enzychem LifeSciences EC-18 patients with acute respiratory distress syndrome (ARDS) due to COVID-19 pneumonia IND approved by the FDA for phase 2 trial
Accelerate Diagnostics BioCheck SARS-CoV-2 IgM and IgG Combo Test and fully automated MS-Fast instrument COVID-19 antibody test Emergency Use Authorization (EUA) granted by the FDA
LumiraDx LumiraDx SARS-CoV-2 antigen test detection of SARS-CoV-2 antigens EUA granted by the FDA
Other Trials and Actions
CARsgen Therapeutics CT041 claudin18.2-positive solid tumors IND approved by the FDA
Acepodia ACE1702 HER2-expressing solid tumors first patients dosed in phase 1 trial
Arrowhead Pharmaceuticals ARO-HIF2 clear-cell renal cell carcinoma first patients dosed in phase 1b trial
Enterprise Therapeutics ETD002 all cystic fibrosis patients, independent of genotype first patients dosed in phase 1 trial
Epirium Bio EPM-01 Becker muscular dystrophy enrollment of first patients in phase 1 trial
Immunic IMU-856 diarrhea-predominant irritable bowel syndrome (IBS-D), ulcerative colitis (UC) and Crohn's disease dosing of first patients in phase 1 trial
I-Mab plonmarlimab (TJM2) rheumatoid arthritis dosing of first patient in phase 1b trial
Pluristem Therapeutics PLX-R18 incomplete hematopoietic recovery following hematopoietic cell transplantation patient enrollment complete in phase 1 trial
Ultimovacs ASA UV1 in combination with pembrolizumab metastatic malignant melanoma patient enrollment complete in phase 1 trial
4D Molecular Therapeutics 4D-125 X-linked retinitis pigmentosa initiation of phase 1/2 trial
Trefoil Therapeutics TTHX1114 regenerative treatment of corneal endothelial dystrophies initiation of phase 1/2 trial
Alkermes ALKS 4230 advanced, malignant solid tumors initiation of phase 2 trial
Amplyx MAU868 BK viremia in kidney transplant recipients dosing of first patient in phase 2 trial
Ascletis Pharma ASC22 (Envafolimab) chronic hepatitis B dosing of first patient in phase 2a trial
AzurRx MS1819 cystic fibrosis patients with exocrine pancreatic insufficiency dosing of first patients in phase 2b trial
Imara IMR-687 adult patients with sickle cell disease dosing of first patient in phase 2b trial
Neuroptika NRO-1 dry eye disease patient enrollment complete in phase 2 trial
Verona Pharma pressurized metered-dose inhaler (pMDI) formulation of ensifentrine moderate to severe chronic obstructive pulmonary disease initiation of phase 2 trial
BioLineRx motixafortide (BL-8040) mobilization of hematopoietic stem cells for autologous transplantation in patients with multiple myeloma patient enrollment complete in phase 2 trial
Endospan NEXUS Aortic Arch Stent Graft System thoracic aortic arch disease IDE approved by the FDA
4D Molecular Therapeutics 4D-310 Fabry Disease Fast Track designation granted by the FDA
Akeso Biopharma AK104 patients with recurrent or metastatic squamous cervical cancer who have disease progression on or after platinum-based chemotherapy Fast Track designation granted by the FDA
Precision Biosciences PBCAR0191 advanced B-cell precursor acute lymphoblastic leukemia Fast Track designation granted by the FDA
Mustang Bio MB-107 X-linked severe combined immunodeficiency in newly diagnosed infants Rare Pediatric Disease designation granted by the FDA
Scholar Rock SRK-015 spinal muscular atrophy Rare Pediatric Disease designation granted by the FDA
Genentech Enspryng (satralizumab-mwge) adults with AQP4 antibody-positive neuromyelitis optica spectrum disorder approved by the FDA
RapidAI Rapid LVO detecting suspected large vessel occlusions approved by the FDA

 

Upcoming Events

Featured Products

Featured Stories

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here